

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

## **Bulletin from the extraordinary general meeting in Cyxone AB on 18 April 2023**

**Today, on 18 April 2023, an extraordinary general meeting was held in Cyxone AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.**

The extraordinary general meeting resolved, in accordance with the proposal from the Nomination Committee, that the board of directors shall compose of three board members for the time until the close of the next annual general meeting.

It was further resolved, in accordance with the proposal from the Nomination Committee, to elect Carl-Magnus Högerkorp as new board member alongside the current board members Bert Junno and Mikael Lindstam, and that no remuneration shall be paid to the new board member.

### **Malmö on 18 April 2023**

Cyxone AB (publ)

#### **Contact**

Carl-Magnus Högerkorp  
CEO, Cyxone AB  
Tel: +46 (0)70 781 88 12  
Email: [carl.hogerkorp@cyxone.com](mailto:carl.hogerkorp@cyxone.com)

*The information was submitted for publication, through the agency of the contact person set out above, on 18 April 2023.*

#### **About Cyxone**

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit [www.cyxone.com](http://www.cyxone.com)